https://scholars.lib.ntu.edu.tw/handle/123456789/469774
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Lin T.-H. | en_US |
dc.contributor.author | Chuang S.-Y. | en_US |
dc.contributor.author | Chu C.-Y. | en_US |
dc.contributor.author | Lee W.-H. | en_US |
dc.contributor.author | Hsu P.-C. | en_US |
dc.contributor.author | Su H.-M. | en_US |
dc.contributor.author | Li Y.-H. | en_US |
dc.contributor.author | Fang C.-C. | en_US |
dc.contributor.author | Wang K.-Y. | en_US |
dc.contributor.author | Tseng W.-K. | en_US |
dc.contributor.author | Li A.-H. | en_US |
dc.contributor.author | Ueng K.-C. | en_US |
dc.contributor.author | Hsieh I.-C. | en_US |
dc.contributor.author | Huang L.-C. | en_US |
dc.contributor.author | Wang C.-H. | en_US |
dc.contributor.author | Pan W.-H. | en_US |
dc.contributor.author | Yeh H.-I. | en_US |
dc.contributor.author | CHAU-CHUNG WU | en_US |
dc.contributor.author | Yin W.-H. | en_US |
dc.contributor.author | Chen J.-W. | en_US |
dc.creator | Lin T.-H.;Chuang S.-Y.;Chu C.-Y.;Lee W.-H.;Hsu P.-C.;Su H.-M.;Li Y.-H.;Fang C.-C.;Wang K.-Y.;Tseng W.-K.;Li A.-H.;Ueng K.-C.;Hsieh I.-C.;Huang L.-C.;Wang C.-H.;Pan W.-H.;Yeh H.-I.;Chau-Chung Wu;Yin W.-H.;Chen J.-W. | - |
dc.date.accessioned | 2020-03-04T09:03:09Z | - |
dc.date.available | 2020-03-04T09:03:09Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1449-1907 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896737477&doi=10.7150%2fijms.7069&partnerID=40&md5=7098168b01bf5afbb188973f3e4d2cdd | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/469774 | - |
dc.description.abstract | Background: Patients with chronic kidney disease (CKD) is a very high risk cardiovascular disease population and should be treated aggressively. We investigated lipid management in CKD patients with atherosclerosis in Taiwan. Methods: 3057 patients were enrolled in a multi-center study (T-SPARCLE). Lipid goal are defined as total cholesterol (TC) < 160mg/dl, low-density lipoprotein (LDL) <100 mg/dl, high-density lipoprotein (HDL) > 40 mg/dl in men, HDL > 50 mg/dl in women, non-HDL cholesterol < 130mg/dl, and triglyceride < 150 mg/dl. Results: Compared with those without CKD (n=2239), patients with CKD (n=818) had more co-morbidities (hypertension, glucose intolerance, stroke and heart failure) and lower HDL but higher triglyceride levels. Overall 2168 (70.5%) patients received lipid-lowering agents. There was similar equivalent statin potency between CKD and non-CKD groups. The goal attainment is lower in HDL and TG in the CKD group as compared with non-CKD subjects (47.1 vs. 51.9% and 63.2 vs. 68.9% respectively, both p < 0.02). Analysis of sex and CKD interaction on goals attainment showed female CKD subjects had lower non-HDL and TG goals attainment compared with non-CKD males (both p < 0.019). Conclusion: Although presenting with more comorbidities, the CKD population had suboptimal lipid goal attainment rate as compared with the non-CKD population. Further efforts may be required for better lipid control especially on the female CKD subjects. ? Ivyspring International Publisher. | - |
dc.publisher | Ivyspring International Publisher | - |
dc.relation.ispartof | International Journal of Medical Sciences | - |
dc.subject | Atherosclerosis; Chronic kidney disease; Goal; Lipid | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | acetylsalicylic acid; acipimox; alpha adrenergic receptor blocking agent; angiotensin receptor antagonist; antilipemic agent; calcium channel blocking agent; cholesterol; clopidogrel; colestyramine; dipeptidyl carboxypeptidase inhibitor; diuretic agent; ezetimibe; fibric acid derivative; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; triacylglycerol; aged; article; atherosclerosis; cerebrovascular accident; cholesterol blood level; chronic kidney disease; comorbidity; controlled study; disease control; drug use; dyslipidemia; female; glucose intolerance; goal attainment; heart failure; human; hypertension; major clinical study; male; sex; Taiwan; triacylglycerol blood level; atherosclerosis.; chronic kidney disease; goal; lipid; Atherosclerosis; Cross-Sectional Studies; Female; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Male; Multivariate Analysis; Renal Insufficiency, Chronic; Taiwan; Triglycerides | - |
dc.title | The impact of chronic kidney disease on lipid management and goal attainment in patients with atherosclerosis diseases in Taiwan | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.7150/ijms.7069 | - |
dc.identifier.pmid | 24578616 | - |
dc.identifier.scopus | 2-s2.0-84896737477 | - |
dc.relation.pages | 381-388 | - |
dc.relation.journalvolume | 11 | - |
dc.relation.journalissue | 4 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Medical Education and Bioethics | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0001-8191-475X | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學教育暨生醫倫理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。